# Empagliflozin to Prevent Post-Operative Atrial Fibrillation

> **NCT06124937** · PHASE3 · UNKNOWN · sponsor: **Rajaie Cardiovascular Medical and Research Center** · enrollment: 492 (estimated)

## Conditions studied

- Post-operative Atrial Fibrillation
- CABG

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06124937
- **Lead sponsor:** Rajaie Cardiovascular Medical and Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-07
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 492 (ESTIMATED)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06124937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06124937, "Empagliflozin to Prevent Post-Operative Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06124937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*